BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35615365)

  • 1. Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination.
    Paschold L; Klee B; Gottschick C; Willscher E; Diexer S; Schultheiß C; Simnica D; Sedding D; Girndt M; Gekle M; Mikolajczyk R; Binder M
    Front Immunol; 2022; 13():876306. PubMed ID: 35615365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination.
    Schaefer-Babajew D; Wang Z; Muecksch F; Cho A; Loewe M; Cipolla M; Raspe R; Johnson B; Canis M; DaSilva J; Ramos V; Turroja M; Millard KG; Schmidt F; Witte L; Dizon J; Shimeliovich I; Yao KH; Oliveira TY; Gazumyan A; Gaebler C; Bieniasz PD; Hatziioannou T; Caskey M; Nussenzweig MC
    Nature; 2023 Jan; 613(7945):735-742. PubMed ID: 36473496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.
    Park S; Choi J; Lee Y; Noh J; Kim N; Lee J; Cho G; Kim S; Yoo DK; Kang CK; Choe PG; Kim NJ; Park WB; Kim S; Oh MD; Kwon S; Chung J
    Nat Commun; 2024 Apr; 15(1):3368. PubMed ID: 38643233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection.
    Zhang Y; Yan Q; Luo K; He P; Hou R; Zhao X; Wang Q; Yi H; Liang H; Deng Y; Hu F; Li F; Liu X; Feng Y; Li P; Qu L; Chen Z; Pan-Hammarström Q; Feng L; Niu X; Chen L
    J Virol; 2022 Feb; 96(4):e0160021. PubMed ID: 34878902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint.
    Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H
    BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults.
    Um J; Choi YY; Kim G; Kim MK; Lee KS; Sung HK; Kim BC; Lee YK; Jang HC; Bang JH; Chung KH; Oh MD; Park JS; Jeon J
    J Korean Med Sci; 2022 Mar; 37(9):e70. PubMed ID: 35257525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses.
    Buckner CM; Kardava L; El Merhebi O; Narpala SR; Serebryannyy L; Lin BC; Wang W; Zhang X; Lopes de Assis F; Kelly SEM; Teng IT; McCormack GE; Praiss LH; Seamon CA; Rai MA; Kalish H; Kwong PD; Proschan MA; McDermott AB; Fauci AS; Chun TW; Moir S
    Cell; 2022 Nov; 185(23):4333-4346.e14. PubMed ID: 36257313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.